Opioid Distributors Sold ‘Mountain of Pills,’ Lawyer Tells Judge
(Bloomberg) --
The biggest drug distributors in the U.S. were accused of swamping a West Virginia county with millions of doses of painkillers as testimony is set to begin in the first trial over the companies' role in the opioid crisis is set to begin.
McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Corp. wrongfully “sold a mountain of opioid pills into our community, fueling the opioid epidemic,” Paul Farrell, a lawyer for Cabell County, told a judge Monday in his opening statement. The county and the city of Huntington want distributors to pay $2.6 billion to beef up treatment and policing budgets strained by years of opioid overdoses and addictions.
Drug distributors, manufacturers and retailers face thousands of similar lawsuits by state and local governments nationwide over the opioid crisis in which 400,000 Americans have died in the past two decades. West Virginia has been among the hardest-hit states, with Cabell County's overdose-death rate being more than five times the national average during the period covered by the suit, according to researchers.
Most of the suits claim the companies created a public nuisance through their marketing and supply of opioids. It's one of the first times states and governments aimed the law at cases that don't involve property or pollution disputes.
Read More: Purdue's $40 Trillion of Opioid Claims Top Size of U.S. Economy
In the West Virginia case, the distributors argue that public-nuisance law can't be applied to their deliveries of painkillers to local retailers over a nine-year period starting in 2005 because the opioid pills were approved by federal regulators and the supply chain was licensed by the state.
Huntington and Cabell County want U.S. District Judge David Faber, who's hearing the case without a jury, to improperly hold the distributors responsible for causing the opioid epidemic in their areas, said Robert Nicholas, a lawyer for AmerisourceBergen.
The root of the problem is illegal drugs shipped in by “gangs and drug dealers, who've preyed” on the local governments for almost 20 years, Nicholas told Faber. “That continues to this day.”
Nicholas also dismissed the governments' demand for billions of dollars to address the public-health crisis as “absurd.”
“It's not a recovery plan,” he said. “It's a litigation plan.”
The distributors also shouldn't be held liable for marketing opioids since all they did was communicate to customers what types of drugs were available and the prices, said Enu Mainigi, one of Cardinal Health's attorneys.
Unlike opioid makers such as Johnson & Johnson and Purdue Pharma LP, “distributors don't send sales reps to doctors' offices to persuade them to write more” painkiller prescriptions, she said in her opening statement.
Proof Required
Paul Schmidt, one of McKesson's lawyers, argued the municipalities' decision to proceed under nuisance laws still requires proof the distributors' handling of the pills damaged their communities. “Public nuisance aren't some kind of magic words,” he said. “They still must show the defendants caused harm.”
The trial comes as McKesson, Cardinal Health and AmerisourceBergen -- along with J&J -- are proposing a $26 billion global settlement of all opioid suits. The distributors would pay a combined $21 billion while J&J would put up $5 billion, according to regulatory filings. The deal has yet to be finalized.
In the only other public-nuisance suit to go to trial, a judge in 2019 ordered J&J to pay $465 million to the state of Oklahoma over its marketing of opioid painkillers. While the state had sought more than $17 billion, J&J is appealing the decision.
Corey Waller, an opioid-addiction specialist, is scheduled to testify Tuesday about the effects of synthetic opiates on the human body, followed by David Courtwright, a medical historian who's written about the development of opioid addictions in the U.S.
The case is City of Huntington v. AmerisourceBergen, 17-cv-1362, U.S. District Court, Southern District of West Virginia (Charleston).
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.